Wednesday, October 5

Spain receives this week 5,000 new doses of the monkeypox vaccine


Spain is the European country most affected by monkeypox. Last Friday the number of infections approached 6,500, practically double that of France, Germany or the United Kingdom, the next on the list. The outbreak that began at the end of April and spread rapidly through countries where cases were not usually registered, is one of the current concerns of the WHO, which at the end of July declared it a “public health emergency of international importance”.

The unknowns of an unexpected outbreak: how monkeypox spread throughout the world

Know more

Between this Tuesday and Wednesday, 5,000 more doses of the monkeypox vaccine will arrive, in addition to the 5,300 received in June and the more than 7,000 arrivals in August. With this latest addition, the National Health System (SNS) will add more than 17,000 doses against this virus. The doses of Inmavex come from centralized purchasing from European countries, and come to try to control the spread of monkeypox.

In fact, the shortage of this drug has led the US and European health authorities to authorize the division of each available dose into five, with the aim of immunizing more people with fewer vials. Spain approved a new vaccination strategy a week ago in which it indicates applying 0.1 ml in most cases instead of 0.5 ml as before. This would mean that this week’s shipment could translate into up to 25,000 punctures.


The European Medicines Agency (EMA) bases its decision to change the route of administration on a study conducted with a sample of 500 people in which they saw that the levels of antibodies were similar. Some professionals in both Europe and the United States have questioned whether the sample was large enough to make that decision. The point, in any case, is that doses are scarce and it is important to stop the spread of the virus.

The Public Health Commission agreed that “in people over 18 years of age for whom this vaccine is indicated, a dose of 0.1 ml intradermal will be administered, except for pregnant women and immunosuppressed, to whom a dose of 0.5 ml will be administered. ml cutaneously. This strategy applies both to pre-exposure situations (people with some activity considered risky) and post-exposure situations (direct contacts of a confirmed case).


According to the latest report from the Ministry of Health, most of the cases in Spain are registered in Madrid and Catalonia. Of the 5,780 cases with available information, 197 cases ended in hospitalizations – 3.4% – and two of the cases have died due to meningoencephalitis. In 96% of the cases, it is about men who have sex with men, and it is considered that the most likely mechanism of transmission in 92.6% was through close contact in the context of a sexual relationship and in 7.4 % due to close non-sexual contact.

The Ministry of Health insists on the importance of pre-exposure vaccination for those who have risky sexual relations and those who are administered PREP. Close contacts of infected patients should also receive the drug.



www.eldiario.es